Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
50.48
+1.16 (2.36%)
Aug 10, 2026, 10:48 AM EDT - Market open
Boston Scientific Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 539 | 1,965 | 414 | 865 | 928 | 1,925 |
Cash & Short-Term Investments | 539 | 1,965 | 414 | 865 | 928 | 1,925 |
Cash Growth | 0.94% | 374.64% | -52.14% | -6.79% | -51.79% | 11.02% |
Accounts Receivable | 3,049 | 2,926 | 2,558 | 2,228 | 1,970 | 1,778 |
Inventory | 3,235 | 2,943 | 2,810 | 2,484 | 1,867 | 1,610 |
Other Current Assets | 1,150 | 959 | 1,138 | 936 | 995 | 1,004 |
Total Current Assets | 7,972 | 8,794 | 6,920 | 6,514 | 5,760 | 6,317 |
Net Property, Plant & Equipment | 4,126 | 4,036 | 3,294 | 2,859 | 2,446 | 2,252 |
Other Intangible Assets | 6,918 | 7,019 | 6,684 | 6,003 | 5,902 | 6,121 |
Goodwill | 18,640 | 18,282 | 17,089 | 14,387 | 12,920 | 11,988 |
Long-Term Investments | 2,245 | - | - | - | - | - |
Other Long-Term Assets | 5,314 | 5,541 | 5,409 | 5,372 | 5,442 | 5,552 |
Total Assets | 45,216 | 43,673 | 39,395 | 35,136 | 32,469 | 32,229 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1,231 | 1,144 | 960 | 942 | 862 | 794 |
Accrued Expenses | 2,756 | 3,201 | 2,773 | 2,646 | 2,160 | 2,436 |
Short-Term Debt | 1,709 | 299 | 1,778 | 531 | 20 | 261 |
Other Current Liabilities | 732 | 795 | 887 | 814 | 761 | 783 |
Total Current Liabilities | 6,428 | 5,439 | 6,399 | 4,933 | 3,803 | 4,274 |
Long-Term Debt | 10,915 | 11,137 | 8,968 | 8,571 | 8,915 | 8,804 |
Other Long-Term Liabilities | 2,701 | 2,625 | 2,025 | 2,101 | 2,179 | 2,530 |
Total Long-Term Liabilities | 13,616 | 13,762 | 10,993 | 10,672 | 11,094 | 11,334 |
Total Liabilities | 20,044 | 19,201 | 17,392 | 15,605 | 14,897 | 15,608 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 17 | 17 | 17 | 17 | 17 | 17 |
Treasury Stock | -4,318 | -2,251 | -2,251 | -2,251 | -2,251 | -2,251 |
Additional Paid-in Capital | 21,717 | 21,505 | 21,056 | 20,647 | 20,289 | 19,986 |
Accumulated Other Comprehensive Income | -304 | -610 | 275 | 49 | 269 | 263 |
Retained Earnings | 7,818 | 5,571 | 2,673 | 819 | -750 | -1,392 |
Total Common Shareholders' Equity | 24,930 | 24,233 | 21,770 | 19,282 | 17,573 | 16,622 |
Minority Interest | 242 | 239 | 233 | 248 | - | - |
Shareholders' Equity | 25,172 | 24,472 | 22,003 | 19,530 | 17,573 | 16,622 |
Total Liabilities & Equity | 45,216 | 43,673 | 39,395 | 35,136 | 32,469 | 32,229 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 12,624 | 11,436 | 10,746 | 9,102 | 8,935 | 9,065 |
Net Cash (Debt) | -12,085 | -9,471 | -10,332 | -8,237 | -8,007 | -7,140 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -8.11 | -6.34 | -6.95 | -5.63 | -5.56 | -4.95 |
Book Value | 24,930 | 24,233 | 21,770 | 19,282 | 17,573 | 16,622 |
Book Value Per Share | 16.73 | 16.21 | 14.65 | 13.18 | 12.21 | 11.53 |
Tangible Book Value | -628 | -1,068 | -2,003 | -1,108 | -1,249 | -1,487 |
Tangible Book Value Per Share | -0.42 | -0.71 | -1.35 | -0.76 | -0.87 | -1.03 |